When streptozotocin is injected into the brain, it leads to cognitive impairment and pathophysiological alterations like those found in patients with AD, including cerebral insulin resistance, oxidative stress, tau phosphorylation, and neuroinflammation [35,36]. The gene discussed is MAPT; the disease is Alzheimer disease.